Shenzhen Venture Capital leads $28m Series B round in China’s Hrain Biotech

Hrain Biotechnology, a Chinese company that specializes in the research and development of tumour immunotherapy technologies, has secured 200 million yuan ($27.97 million) in a Series B round of financing led by Chinese state-backed venture capital firm Shenzhen Venture Capital, it announced on Monday.

A group of investors including Chinese private equity firm Xiamen Junyida Capital Management, Shenzhen-based Qianhaiyu Investment, and a healthcare fund jointly launched by Yangming Capital and the local government in southeastern China’s Fujian province, also poured money into the new round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter